1304 - DFCI 10-106 Myeloma

Go Back to BMT CTN Protocol Listing

  • Protocol Short Name and Number:  DFCI 10-106/ BMT CTN 1304 DETERMINATION
  • Protocol Long Name: A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age.
  • Protocol
  • Key Personnel
    • BMT CTN # 1304  Protocol Chair: Paul Richardson
    • BMT CTN # 1304  Protocol Coordinator: Amy Foley afoley@nmdp.org          
  • Keywords: Lenalidomide, Bortezomib, Dexamethasone, RVD, Multiple Myeloma, MM, Quality of Life, QOL, Auto Transplant, Autologous Transplant, Auto, Consolidation, Maintenance, Pediatric, Child, Children, Teen, Adolescent